Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

Similar Items

• DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
  od: Abdel-Wahab, O, i dr.
  Izdano: (2011)
• EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
  od: Patnaik, Mrinal M., i dr.
  Izdano: (2018)
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
  od: Tefferi, A, i dr.
  Izdano: (2009)
• Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms
  od: Abdel-Wahab, Omar, i dr.
  Izdano: (2012)
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
  od: Tefferi, A, i dr.
  Izdano: (2010)